Author:
Jiang Q,Huang H,Liu Q,Sun J,Zhou H,Fan Z,Zhang Y,Huang F,Chai Y,Xu D,Lu Y,Wei Q,Yu G,Li X,Dai M,Xu N,Zhou D,Zhao H,Shen K,Mai Q,Zhou Y,Meng F
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference14 articles.
1. Apperley J, Carreras E, Gluckman E, Masszi T (eds). Early complications after HSCT. The EBMT Handbook on Haematopoietic Stem Cell Transplantation, 6th edn. Forum service editore: Genoa, Italy, 2012, pp 176–179.
2. Khojasteh NH, Zakerinia M, Ramzi M, Haghshenas M . A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients. Transplant Proc 2000; 32: 596.
3. Brock N, Pohl J . The development of MESNA for regional detoxification. Cancer Treat Rev 1983; 10 (Suppl A): 33–43.
4. Haselberger MB, Schwinghammer TL . Efficacy of MESNA for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 1995; 29: 918–921.
5. Korkmaz A, Topal T, Oter S . Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP actication. Cell Biol Toxicol 2007; 23: 303–312.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献